ILC2 mechanism of suppression of GVHD is dependent upon ILC2 expression of IL-13 and AREG. (A) Diagram for B6 into B6D2 transplantation. Each B6D2 recipient received B6 BM and B6 splenic T cells with one group of B6D2 recipients also being given IL-13/Areg DKO ILC2s. Lethally irradiated B6D2 mice received TCD BM (BM only), BM plus total splenic T cells (BM + T cells), or BM plus T cells with activated B10.BR ILC2s (BM, T cells + IL-13/Areg DKO ILC2s). (B) Kaplan-Meier plot of survival following allo-HSCT, 1 representative of 2 experiments shown (n = 5 each experiment), log-rank (Mantel-Cox) test. (C) Clinical score posttransplantation, analyzed by using a two-way analysis of variance, with Bonferroni correction for repeated measures of multiple comparisons. (D) Quantification of FITC-dextran in the serum of BMT recipients described in panel C 28 days after transplant. One representative of 2 independent experiments shown; mean ± standard error of the mean (n = 5 per group). Statistical analysis by Student t test, *P < .05.